Summary
Apolipoprotein B (ApoB) is the structural protein of all atherogenic lipoprotein particles — each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule. Because the number of particles matters for cardiovascular risk (not just the cholesterol they contain), ApoB provides a more accurate measure of true atherogenic burden than LDL-C, particularly in people with metabolic syndrome, diabetes, or high triglycerides.
LDL cholesterol measures the total amount of cholesterol carried in LDL particles. But cardiovascular risk is driven by the number of atherogenic particles penetrating the arterial wall — not the cholesterol concentration. Two people with the same LDL-C can have very different particle numbers: small, dense LDL particles carry less cholesterol per particle but more particles for the same LDL-C level.
ApoB directly counts all atherogenic lipoprotein particles. Studies consistently show that ApoB predicts cardiovascular events better than LDL-C, particularly in people with metabolic syndrome, where atherogenic dyslipidaemia (high triglycerides, low HDL, small dense LDL) produces discordance between LDL-C and true particle burden.
Most major cardiovascular guidelines now recommend ApoB measurement alongside or instead of LDL-C as the primary treatment target.
What It Is
Apolipoprotein B exists in two isoforms: ApoB-100 (produced by the liver — present on LDL, VLDL, IDL, and Lp(a) particles) and ApoB-48 (produced in the gut — present on chylomicrons). Routine laboratory ApoB measurement detects ApoB-100 specifically, capturing all hepatic atherogenic particles.
The key insight is the one-to-one relationship: each LDL, VLDL, and IDL particle contains exactly one ApoB-100 molecule. Therefore, serum ApoB concentration directly equals the number of atherogenic particles in circulation (in nmol/L, which correlates with particles/litre).
ApoB is measured in g/L and does not require fasting. Reference ranges: men < 1.10 g/L (optimal < 0.80 g/L); women < 1.00 g/L (optimal < 0.80 g/L).
Functions
Atherogenic particle counter
One ApoB per atherogenic particle makes it the most direct measure of the particles actually penetrating arterial walls — the root cause of atherosclerosis.
Superior risk predictor in metabolic syndrome
ApoB identifies cardiovascular risk in people with normal LDL-C but high triglycerides and insulin resistance — a common and dangerous discordance.
Treatment target (emerging)
Major cardiology guidelines increasingly recommend ApoB < 0.80 g/L as the primary treatment target — equivalent to LDL-C < 1.8 mmol/L.
Lipid pattern characterisation
ApoB:ApoA1 ratio is a powerful cardiovascular risk index, particularly in metabolic syndrome where standard lipids may appear deceptively normal.
Reference Ranges
Apolipoprotein B (ApoB)
Measured in g/L| Status | Range (g/L) | Range (mg/dL) | What it means |
|---|---|---|---|
| Optimal | < 0.80 | < 80 | Low atherogenic particle burden — equivalent to LDL-C < 1.8 mmol/L. Ideal for CVD prevention. |
| Borderline | 0.80–1.10 | 80–110 | Moderate particle burden — assess overall cardiovascular risk and treat if indicated. |
| Elevated | > 1.10 | > 110 | High atherogenic particle burden — cardiovascular risk significantly elevated. Active management required. |
ApoB targets depend on cardiovascular risk: primary prevention < 1.00 g/L; high risk < 0.80 g/L; very high risk < 0.65 g/L (ESC 2021). ApoB does not require fasting.
Symptoms of Imbalance
Elevated ApoB is asymptomatic — it represents silent plaque-building risk.
- Very low ApoB from statin or PCSK9 inhibitor therapy is well-tolerated
- Extremely rare genetic ApoB deficiency (abetalipoproteinaemia) causes fat malabsorption
- Asymptomatic — consequences manifest as heart attack or stroke after years
- Xanthelasma or tendon xanthomata in familial hypercholesterolaemia
Causes of Imbalance
- Statin therapy
- PCSK9 inhibitors
- Low saturated fat diet
- Very rare: familial hypobetalipoproteinaemia
- Familial hypercholesterolaemia
- Metabolic syndrome and insulin resistance
- Type 2 diabetes
- Hypertriglyceridaemia
- Obesity
- High saturated fat diet
- Hypothyroidism
FAQs
LDL-C measures the total cholesterol in LDL particles, but not how many particles there are. A person with many small LDL particles can have the same LDL-C as someone with fewer, larger particles — but the former carries more cardiovascular risk because more particles are available to penetrate the arterial wall. ApoB counts each particle directly (1 ApoB per particle), giving a more accurate measure of true atherogenic burden.
The ApoB:ApoA1 ratio divides atherogenic particles (ApoB) by protective HDL particles (ApoA1). A ratio above 0.9 in men or 0.8 in women is associated with significantly elevated cardiovascular risk. In the INTERHEART study, ApoB:ApoA1 was the strongest lipid predictor of myocardial infarction — stronger than any individual lipid measure.
Ideally both — they provide complementary information. In people without metabolic risk factors, LDL-C and ApoB track closely. ApoB is particularly valuable when LDL-C and ApoB are discordant — i.e. when you have elevated triglycerides, metabolic syndrome, diabetes, or obesity. In these conditions, LDL-C may be falsely reassuring while ApoB reveals a high atherogenic particle burden.
No — ApoB does not require fasting. Because ApoB measures particles (not triglyceride-rich content), post-prandial chylomicron fluctuations have minimal impact on the ApoB-100 measurement from hepatic particles. This makes ApoB more convenient than triglycerides and non-HDL for repeat monitoring.
Major guidelines recommend an ApoB target of < 0.80 g/L for people with high cardiovascular risk, and < 0.65 g/L for very high-risk patients (established CVD, diabetes with organ damage, FH with CVD). These targets correspond approximately to LDL-C < 1.8 mmol/L and < 1.4 mmol/L respectively. ApoB responds well to statin therapy — monitoring it alongside LDL-C confirms that treatment is achieving adequate particle reduction.
References
- Sniderman AD, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337–345. View source
- Yusuf S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–1649. View source
- ESC/EAS Guidelines for the management of dyslipidemias 2021. Eur Heart J. 2020;41(1):111–188. View source